Yes, we do continue CFTR modulators in post-transplant patients for benefits to other organs like sinuses, GI tract, pancreas and perhaps liver. We have to modify and adjust for transplant medication for dosing and interactions. Unfortunately, there is not a large evidence base supporting this pract...